Agenus Target of Unusually High Options Trading (NASDAQ:AGEN)

Posted by Stanley Muller on Jul 15th, 2026

Agenus Inc. (NASDAQ:AGEN – Get Free Report) saw unusually large options trading on Monday. Stock traders purchased 9,107 call options on the stock. This represents an increase of approximately 2,764% compared to the average daily volume of 318 call options.

Institutional Trading of Agenus

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Agenus by 1.5% during the third quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock valued at $9,893,000 after purchasing an additional 36,983 shares during the period. Renaissance Technologies LLC lifted its position in Agenus by 721.1% in the fourth quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after purchasing an additional 477,346 shares during the period. AQR Capital Management LLC lifted its position in Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares during the period. Marshall Wace LLP acquired a new stake in Agenus during the second quarter worth $1,976,000. Finally, Bank of America Corp DE boosted its stake in Agenus by 110.0% during the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after buying an additional 220,327 shares in the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Price Performance

NASDAQ AGEN opened at $5.08 on Wednesday. The company’s fifty day moving average is $3.37 and its two-hundred day moving average is $3.45. Agenus has a 52-week low of $2.71 and a 52-week high of $8.70. The firm has a market capitalization of $211.53 million, a price-to-earnings ratio of 3.19 and a beta of 1.55.

Agenus (NASDAQ:AGEN – Get Free Report) last released its earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($1.08). Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. The company had revenue of $33.74 million during the quarter, compared to the consensus estimate of $129.50 million. As a group, sell-side analysts expect that Agenus will post 0.02 earnings per share for the current fiscal year.

Trending Headlines about Agenus

Here are the key news stories impacting Agenus this week:

Positive Sentiment: Agenus secured an oversubscribed private placement that could provide up to $340 million, with about $85 million upfront and the rest potentially coming from warrant exercises. The deal is intended to fund its registrational Phase 3 ROBBIN trial in microsatellite-stable colon cancer and extend the company’s cash runway. Article Title
Positive Sentiment: Management is narrowing its focus to the BOT+BAL combination and the ROBBIN study, while stepping back from the BATTMAN metastatic colorectal cancer program. Investors are rewarding the clearer strategy and concentration of resources on the more promising neoadjuvant colon cancer opportunity. Article Title
Neutral Sentiment: HC Wainwright cut near-term EPS estimates for 2026, even while keeping a Buy rating and a $30 price target. That suggests analysts see execution risk in the near term, but still believe the stock has meaningful upside if the strategy works. Article Title
Negative Sentiment: Some of the move may reflect profit-taking after the stock’s huge run-up, and there is also concern that the rally may be overstretched until investors see clinical progress and financing milestones. Article Title

Analysts Set New Price Targets

AGEN has been the topic of a number of recent analyst reports. Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright upped their target price on Agenus from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d)” rating on shares of Agenus in a report on Tuesday, June 16th. Finally, Wall Street Zen upgraded Agenus from a “hold” rating to a “buy” rating in a report on Monday, April 6th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.00.

Read Our Latest Research Report on Agenus

About Agenus

(Get Free Report)

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.